Impact News +++ Insiderhandel: Vorstand kauft Aktien von SBF im Wert von 12000 EUR (Insiderkauf) +++ SBF AG Aktie -4,13%

ANAPTYSBIO Aktie

>ANAPTYSBIO Aktienkurs

50.74 EUR +5.8% (TradegateBSX)

Ask: 50.78 EUR / 99 Stück

Bid: 49.55 EUR / 101 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ANAPTYSBIO Aktie über LYNX handeln

Intraday

1 Jahr

>ANAPTYSBIO Performance

1 Woche: +5,4%

1 Monat: -2,2%

3 Monate: -2,2%

6 Monate: -9,5%

1 Jahr: +176,2%

laufendes Jahr: +12,6%

>ANAPTYSBIO Aktie

Profil:

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfuncti..
>Volltext..

Insiderhandel:

>ANAPTYSBIO Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>ANAPTYSBIO Peer Group

Gesundheit, Antikörper- Behandlung, Rheuma- Behandlung, Hauterkrankungen & -behandlung/ Dermatologie, Magen-Darm-Erkrankungen & -behandlung
>Alle Branchen..

>ANAPTYSBIO Chart & Kurs - NASDAQ

>ANAPTYSBIO News

22.09.26 - 03:06	AnaptysBio Aktie legt nachbörslich zu: Umsatz übertrifft Erwartungen deutlich (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.09.26 - 01:00	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
	AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

21.09.26 - 22:24	AnaptysBio GAAP EPS of $5.11 beats by $5.02, revenue of $27.5M beats by $7.38M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.09.26 - 22:18	Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update....

19.05.26 - 17:30	Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? (Zacks)
	The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

14.05.26 - 17:30	AnaptysBio (ANAB) May Find a Bottom Soon, Here′s Why You Should Buy the Stock Now (Zacks)
	After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term....

12.05.26 - 22:39	AnaptysBio GAAP EPS of -$1.84 misses by $1.04, revenue of $25.56M beats by $6.69M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.26 - 22:18	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update....

11.05.26 - 15:18	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors (GlobeNewswire EN)
	SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors....

06.05.26 - 19:45	AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy? (Zacks)
	Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out....

04.05.26 - 22:18

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire EN)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET....

28.04.26 - 10:12	Amended: GSK′s Tesaro Provides Update On Anticipatory Breach Claim In AnaptysBio Litigation (AFX)
	LONDON (dpa-AFX) - GSK plc (GSK, GSK.L), subsidiary Tesaro, Inc. (TSRO), on Monday, said the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. (ANAB) against Tesa......

28.04.26 - 10:01	Amended: GSK′s Tesaro Provides Update Anticipatory Breach Claim In AnaptysBio Litigation (AFX)
	LONDON (dpa-AFX) - GSK plc (GSK, GSK.L), subsidiary Tesaro, Inc. (TSRO), on Monday, said the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. (ANAB) against Tesa......

27.04.26 - 20:54	AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim (Benzinga)
	AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the latest technical outlook and more. Importance Rank: 1 read more...

27.04.26 - 17:30	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
	AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

27.04.26 - 16:06	GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.04.26 - 16:01	AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? (Zacks)
	AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

27.04.26 - 11:24	US court rules against GSK in dispute with AnaptysBio (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

27.04.26 - 09:48	GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.04.26 - 09:12	GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werde nie so reich an Geist, dass arm Du würdest am Herzen! - Otto Ludwig

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram